Humana and Pfizer Form Research Partnership
- Details
- Category: Pfizer
Humana Inc. (NYSE: HUM) and Pfizer Inc. (NYSE: PFE) today announced a five-year research partnership to explore new ideas and ways to improve the quality, outcomes and costs of the health care delivery system for senior citizens and other populations.
New Study Shows Cialis® Significantly Improved Study Endpoints
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) announced today that a pivotal Phase III study of Cialis® (tadalafil) tablets 5 mg for once daily use met its co-primary endpoints, significantly improving measures of both erectile dysfunction (ED) and signs and symptoms of benign prostatic hyperplasia (BPH) in men with both conditions.
Bristol-Myers Squibb Foundation Announces Collaboration with World Health Organization's Stop TB Department
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb Foundation today announced a collaboration with the World Health Organization's (WHO) Stop TB Department for a two-year pilot initiative to strengthen community based prevention, care and control of tuberculosis (TB) including co-infection with HIV in South Africa, Tanzania, Kenya, Ethiopia and Democratic Republic of the Congo.
AstraZeneca increases investment in China with new $200 million manufacturing facility
- Details
- Category: AstraZeneca
AstraZeneca today announced a $200 million investment in a new manufacturing facility, located in China Medical City (CMC), Taizhou, Jiangsu province. The new site, which represents AstraZeneca's largest ever investment in a single manufacturing facility globally, will produce both intravenous and oral solid medicines for the company's growing business in China.
Findings from Two-Year Pivotal Phase III TEMSO Trial
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine (NEJM).
Boehringer Ingelheim and Gilead sign license agreement for novel HIV non-catalytic integrase inhibitors
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Gilead Sciences, Inc. (Nasdaq: GILD) have entered into a licensing agreement, under which Boehringer Ingelheim has granted Gilead exclusive worldwide rights for the research, development and commercialization of its novel non-catalytic site integrase inhibitors (NCINIs) for HIV.
Pfizer Announces Licensing Agreement With Puma Biotechnology
- Details
- Category: Pfizer
Pfizer Inc. announced an agreement with Puma Biotechnology, Inc. for the development and commercialization of neratinib, an investigational oral, multi-targeted inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases, being studied for the treatment of cancer.
More Pharma News ...
- Abbott Enrolls First U.S. Patient in Global EXCEL Trial
- Merck and Ono Pharmaceutical Form Collaborations
- BRILIQUE receives a positive preliminary medical benefit assessment
- Merck Publishes 2010 Global Corporate Responsibility Report
- Takeda completes acquisition and names new CEO of Nycomed
- NABP and Pfizer Partner to Educate Patients About The Flood of Counterfeit Medicines Online
- Lilly Launches Open Innovation Drug Discovery Platform